Takeda Pharmaceutical (NYSE:TAK) Upgraded at Wall Street Zen

Takeda Pharmaceutical (NYSE:TAK) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

A number of other brokerages also recently issued reports on TAK. Zacks Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Finally, Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, June 23rd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock opened at $17.15 on Friday. The firm has a 50 day simple moving average of $16.12 and a 200-day simple moving average of $16.97. The stock has a market cap of $54.59 billion, a price-to-earnings ratio of 43.98 and a beta of -0.07. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.09 and a quick ratio of 0.60. Takeda Pharmaceutical has a 1-year low of $12.99 and a 1-year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The firm had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. On average, analysts expect that Takeda Pharmaceutical will post 1.12 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TAK. JPMorgan Chase & Co. raised its holdings in Takeda Pharmaceutical by 37.7% during the third quarter. JPMorgan Chase & Co. now owns 247,529 shares of the company’s stock worth $3,624,000 after purchasing an additional 67,770 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Takeda Pharmaceutical during the 4th quarter worth approximately $998,000. Sivia Capital Partners LLC acquired a new position in shares of Takeda Pharmaceutical in the 2nd quarter valued at $351,000. Bleakley Financial Group LLC boosted its holdings in shares of Takeda Pharmaceutical by 19.0% in the 1st quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock valued at $7,993,000 after buying an additional 68,844 shares in the last quarter. Finally, Assetmark Inc. grew its position in shares of Takeda Pharmaceutical by 27.7% in the 4th quarter. Assetmark Inc. now owns 156,120 shares of the company’s stock valued at $2,434,000 after buying an additional 33,902 shares during the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.